Ankrin Therapeutics is a biotech start-up developing first-in-class drugs for cancer treatment. Our novel and unique therapeutic strategies, founded on forefront high quality research in cancer biology, target essential protein-protein interactions required for error-free DNA damage repair. We will leverage novel, proprietary, and well-characterized protein targets to develop first-in-class drugs against homologous recombination. Our drug discovery pipeline combines both structure-based drug design and high-throughput screening strategies.